Guardant Health Q3 adjusted EBITDA misses estimates
GH•Guardant Health reported Q3 adjusted EBITDA of negative $37.30 million, missing the $36.49 million estimate, while revenue rose 36% to $361 million. The company raised its 2026 revenue guidance to $1.36 billion-$1.37 billion.
1. Quarterly results
Guardant Health’s Q3 revenue rose 36% to $361 million, above the $350.36 million estimate. Its adjusted loss per share of $0.29 beat the $0.32 estimate, but adjusted EBITDA was negative $37.30 million, compared with an estimated loss of $36.49 million.
2. Raised 2026 outlook
The company raised its 2026 revenue guidance to $1.36 billion-$1.37 billion from $1.34 billion-$1.36 billion. It now expects screening revenue of $233 million-$238 million, with Shield test volume of 285,000-290,000, and forecasts a 65% non-GAAP gross margin, up from prior guidance of 64%-65%. Screening revenue rose 180% in Q3, mainly due to a 246% increase in Shield test volume; commercial coverage for Shield expanded to more than 80% of eligible lives.
